Edited By: Roberta Melander
Featured Article

"Fragment based drug design (FBDD) has become a standard methodology in the drug industry. This paradigm dates back to 1996 with publication of the landmark paper in Science. The paradigm depends on screening of small, generally 250 to 300 Da, compounds termed fragments, which record weak affinities often in the millimolar range. These inhibitors can then be grown or linked up to form tight binding inhibitors. FBDD samples more chemical space than larger molecules, so smaller chemical libraries can be used. While the methodology has been notably successful, the use of linking strategies has lagged behind.
This review by Elizabeth Bedwell, William McCarthy, Anthony Coyne, and (the late) Chris Abell, a leading scientist in this field, looks at linker structure and how it relates to the properties of the final ligand. Dynamic combinatorial chemistry and kinetic target- guided synthesis, are highlighted as methods to watch. Linker design is a similarly difficult area for proteolysis targeted chimeras (PROTACs), and maybe there are some useful tips in this analysis."
- David Selwood
- Discovering high-affinity ligands for proteins: SAR by NMR. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Science. 1996. 274(5292):1531-4.
- Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. Howard N, Abell C, Blakemore W, Chessari G, Congreve M, Howard S, Jhoti H, Murray CW, Seavers LC, van Montfort RL. J Med Chem. 2006 Feb 23;49(4):1346-55.
Linker design for Fragment Based Drug Design
Free to Read for a limited time!
On the Cover
Articles
Sphingosine kinase-2 silencing modulates sensitivity of HT-29 human colorectal cancer cells to paclitaxel-induced cell death through altering apoptosis-related proteins
-  17 March 2023
Therapeutic efficacy of caffeic acid phenethyl ester in cancer therapy: An updated review
-  17 March 2023
Perspectives on cutting-edge nanoparticulate drug delivery technologies based on lipids and their applications
-  13 March 2023
Stat5 inhibits NLRP3-mediated pyroptosis to enhance chemoresistance of breast cancer cells via promoting miR-182 transcription
-  11 March 2023
Current understanding and future prospects on Berberine for anticancer therapy
-  11 March 2023
Graphical Abstract

Berberine have been shown in in vitro and in vivo studies to inhibit various types of cancer by activating the p-53 and cyclin-B expression, targeting various cell signaling pathways, to regulate the cell cycle. It also inhibits invasion and metastasis of cancer cells. Beside this it induces the cell death by apoptosis, autophagy and necrosis in cancer cells.
Sphingosine kinase-2 silencing modulates sensitivity of HT-29 human colorectal cancer cells to paclitaxel-induced cell death through altering apoptosis-related proteins
- Chemical Biology & Drug Design
-  17 March 2023
Stat5 inhibits NLRP3-mediated pyroptosis to enhance chemoresistance of breast cancer cells via promoting miR-182 transcription
- Chemical Biology & Drug Design
-  11 March 2023
Current understanding and future prospects on Berberine for anticancer therapy
- Chemical Biology & Drug Design
-  11 March 2023
Graphical Abstract

Berberine have been shown in in vitro and in vivo studies to inhibit various types of cancer by activating the p-53 and cyclin-B expression, targeting various cell signaling pathways, to regulate the cell cycle. It also inhibits invasion and metastasis of cancer cells. Beside this it induces the cell death by apoptosis, autophagy and necrosis in cancer cells.
In-vitro and in-vivo anti-leishmanial activity of the hanging sedge flavonoids based on bio- guided fractionation assay
- Chemical Biology & Drug Design
-  9 March 2023